 |
|
|
 |
|
GAVI Clinical Trials Catalogue, 1990-2000 - Your input is important! A first draft of the “GAVI Clinical Trials Catalogue, 1990-2000” is ready for review. Of the three sources of information used to create this catalogue (i.e., Medline, WHO V&B Vaccine Trial Registry, and Experts) it is now up to Experts such as yourself to contribute to keep the catalogue as much updated as possible. This is why we are requesting your cooperation for you to review the disease/s target of the tested vaccine(s) you are acquainted with and correct, add, or delete entries and vaccine clinical trials from the catalogue. |
||
|
GAVI Trials Catalogue, 1990-2000 | |
|
|
Catalogue user's guide | |
|
|
Update form | |
| Instructions: | ||
| 1. | Check
the disease(s) target of the tested vaccine that you are acquainted with. |
|
| 2. | Use
the attached form to add entries and/or vaccine clinical trials not
included (or to correct or to delete them). |
|
| 3. | Send
your corrections to WHO, using e-mail
(please put GAVI CTC in subject line) or fax
(4122 791 4860) or mail to:
|
|
| 4. | For any clarification, please contact us using the above contact details. | |
|
Background |
||
|
One of the objectives of the Global Alliance for Vaccines and Immunization (GAVI) is to accelerate research and development efforts for new vaccines and related products against diseases of special need for the Third World. A Pre-Task Force on Research and Development of GAVI jointly convened with the WHO Intercluster Vaccine Research Initiative a meeting (4-5 November 1999, Geneva) to begin to explore ways to accelerate research on vaccines against GAVI priority diseases, HIV/AIDS, Malaria and TB, as well as vaccines against diseases that lack substantial markets in industrialized countries but are urgently needed in developing countries (" developing market vaccines"). Among the specific recommendations that emerged from that meeting were: |
||
| · | A GAVI Task Force on Research and Development should oversee the preparation of a catalogue of clinical trial facilities in industrialized and developing countries with experience or potential for evaluating vaccines against GAVI priority disease and “developing market vaccines” in phase I-IV clinical trials; | |
| · | This catalogue should be updated annually. | |
